MENU
At RemediumOne, we have extensive experience in executing successful cardiovascular clinical trials. We understand that cardiovascular diseases are a leading cause of morbidity and mortality worldwide, and we're committed to advancing the science in this critical therapeutic area. We specialize in cardiovascular clinical research and have a successful track record of delivering on-time, high-quality trials. Our team is equipped with extensive knowledge and experience to help medium and smaller biotech companies accelerate their trials while working within budgetary constraints. Our team has worked on clinical trials across the spectrum of cardiovascular diseases, including hypertension, heart failure, coronary artery disease, and more. We have a deep understanding of the complex regulatory requirements and clinical trial design considerations that are unique to this therapeutic area. Our expertise and experience in this therapeutic area have made us a trusted partner for clinical trial management services in cardiovascular research.
At RemediumOne, we have extensive experience in executing successful cardiovascular clinical trials. We understand that cardiovascular disease (CVD) is a significant health issue globally, and Sri Lanka is no exception. It includes conditions such as heart disease, stroke, and other disorders that affect the heart and blood vessels. CVD has been a leading cause of morbidity and mortality in Sri Lanka for several years, and we’re committed to advancing the science in this critical therapeutic area.
We specialize in cardiovascular clinical research and have a successful track record of delivering on-time high-quality trials. Our team is equipped with extensive knowledge and experience to help medium and smaller biotech companies accelerate their trials while working within budgetary constraints.
Our team has worked on clinical trials across the spectrum of cardiovascular diseases, including hypertension, heart failure, coronary artery disease, and more. We have a deep understanding of the complex regulatory requirements and clinical trial design considerations that are unique to this therapeutic area.
In addition, we have collaborations with leading global heart research centers such as The George Institute for Global Health and the Public Health Research Institute – Canada. Together, we are working on scalable solutions like the polypill for hypertension reduction.
Our work has been published in major cardiology journals, including NEJM, JAMA Cardiology, and The Lancet.
